Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Zepzelca (lurbinectedin) for the Treatment of Small Cell Lung Cancer

Drug Name

Zepzelca™ (lurbinectedin)

Developer

PharmaMar and Jazz Pharmaceuticals

Therapy Class

Selective oncogenic transcription inhibitor

Product Description

Intravenous infusion

Current Indication

Small cell lung cancer

Market Sector

Oncology

Development Status

Approved in the US
Expand
Close
Close
Close

Go Top